 |
    |
 |
Ming-Chu Hsu, Ph.D.
(Founder, President, CEO and Chairman of the Board)
Dr. Hsu founded TaiGen in 2001, after successfully building the Biotechnology and Pharmaceutical Research Division of National Health Research Institutes of Taiwan as its founding director. She was also the program leader of the National Science and Technology Program in Biotech / Pharmaceutical Research, a program that brought together 62 academic laboratories in Taiwan to conduct mission-oriented research. Before her return to Taiwan in 1998, Dr. Hsu held the title of Research Director, Oncology and Virology for over 10 years at Hoffmann-La Roche, USA Dr. Hsu has extensive experience in establishing world-class drug discovery teams, as well as the experience of clinical development for new drugs in Taiwan. Prior to Roche, Dr. Hsu was an assistant professor at Rockefeller University in New York, and a Research Fellow at the California Institute of Technology at Stanford University. Dr. Hsu obtained her Ph.D. degree in biochemistry from University of Illinois.
?@ |
 |
Show Chung Ho
(Steering Committee Member and Director)
Mr. Ho is the Chairman of SinoPac Financial Holdings. Prior to that, he was the Chairman and of Yuen Foong Yu (YFY), a conglomerate that encompasses businesses in banking, paper manufacturing, publishing and technology-based industries. He has played a key role in the recent development of the biotech industry in Taiwan. In addition to TaiGen, YFY has invested in companies with proprietary technologies for monoclonal antibodies, gene chips and agricultural biotechnology. One of the most respected businessmen in Taiwan, Mr. Ho was trained in mechanical engineering and has a MS degree from University of Wisconsin and a BS degree from National Cheng Kung University of Taiwan.
?@ |
 |
Michael Steinmetz, Ph.D.
(Steering Committee Member and Director)
Dr. Steinmetz is the Managing Director of Clarus Ventures. Prior to that, he was the General Partner at MPM Capital until 2005. Prior to joining MPM in 1997 Dr. Steinmetz spent 10 years at Hoffmann-La Roche, holding the position of Vice President, Pre-clinical Research and Development with over 800 scientists in Nutley, New Jersey, and headed the Central Research in Basel Switzerland. Under his leadership, multiple drug candidates--including recombinant proteins, antibodies and small molecules-- were discovered and moved into clinical trials. He also conceptualized and managed many of Roche's research-stage alliances including the company's first investment in genomics (Millennium) as well as collaborations with Incyte and Caliper. An accomplished scientist with over 130 publications in scientific peer-review journals, Dr. Steinmetz obtained his doctoral degree from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology prior to joining Roche.
?@ |
 |
Jack Lief
(Steering Committee Member and Director)
Mr. Lief is a co-founder of Arena and has served as the President and CEO since April 1997. From 1995 until April 1997, Mr. Lief served as an advisor and consultant to numerous biopharmaceutical organizations. From 1989 to 1994, he served as a Senior Vice President, for corporate development and security of Cephalon. From 1983 to 1989, Mr. Lief served as the Director of Business Development and Strategic Planning for Alpha Therapeutic Corporation. In 1972 Mr. Lief joined Abbott Laboratories where he served until 1983, most recently as the Head of International Marketing Research. Mr. Lief holds a B.A. from Rutgers University and a M.S. in psychology (experimental and neurobiology) from Lehigh University.
?@ |
|
Steve Lee
(Board of the Director and Steering Committee Member)
Mr. Lee is the Special Assistant to the President of China Steel Corporation. Before that, he was the President and CEO of TaiAn Technologies Corporation, a healthcare venture capital firm until 2005. Prior to this position, Mr. Lee was the Executive Vice President and then the President of Taisil Electronic Materials Corporation, a company which produces silicon wafers for the semiconductor manufacturing industry. Mr. Lee has a long and distinguish career at China Steel Corporation and represents China Steel as a board member of both TaiGen Biotechnology and Genmont Biotech. Mr. Lee holds a MBA from the Sloan Fellows Program at the Massachusetts Institute of Technology.
?@ |
|
William Robert Keller
(Board of Director)
Mr. Keller spent more than 30 years of his career at Roche. Prior to joining the board of directors at TaiGen Biotechnology, he was the General Manager of Roche China, Ltd from 1992 to 2003. Under his leadership, Roche became one of the leading pharmaceutical companies in China. Mr. Keller first joined Roche in 1972, being promoted to the position of Deputy General Manager of Roche Brazil and later, General Manager of Roche Columbia, before becoming the General Manager of Roche China.
?@ |
 |
Jing Lin
(Chief Financial Officer, Finance & Administration)
Ms. Lin joined TaiGen Biotechnology in September 2006 as CFO, responsible overall for finance and administration. Prior to joining TaiGen, Ms. Lin served as CFO of Taiwan's Digital United Inc. from 2000 to 2006. While at Digital United, she played a leading role in the private placement of funding from international investors, corporate migration for an IPO preparation in the United States and other strategic initiatives. Previously, Ms. Lin was the Financial Manager at AT&T in the United States, involved in merger and acquisition activities and various other capacities in that capacity. Ms. Lin received a master's degree in business administration from Carnegie Mellon University and a bachelor's degree in business administration from the National Taiwan University.
?@ |
 |
Stephen H. Ip Ph.D.
(Senior Vice President, Global Business Development)
Dr. Ip has over 25 years of experience in the biotech industry. Prior to joining TaiGen Biotechnology, Dr Ip held various management positions including, Vice President of Business Development & the Head of Far East at Matritech, President of American Biogenetic Sciences, President of CytoMed, where he was also the founder. He held the position of Vice President, Technology of T Cell Sciences where he was a co-founder. He was also a founding member of Cambridge Research Lab of Johnson & Johnson. Dr. Ip has extensive experience in business development including successful deals with SmithKline Beecham, Yamanouchi, Mitsubishi, Sysmex, Astra, Chiron, Pfizer, Syntex, Purdue Pharma and others. Dr. Ip received his Ph.D. in 1976 from the University of Virginia Medical School and was a staff fellow at the hematology and oncology department of the University of Pennsylvania Medical School.
?@ |
 |
Philip, Kuo-Lung Huang
(VP Product Development & Marketing General Manager,
TaiGen Beijing office )
Prior to joining TaiGen in 2004, Mr. Huang was with Takeda for six years and held a number of positions including Sales and Marketing Director in Beijing, Asia Marketing Strategic Manager in Osaka, and Sales and Marketing Director in Taiwan. Prior to joining Takeda Taiwan, Mr. Huang was with Sandoz (Novartis) and MSD for 15 years and held various positions, most recently the Director of Business Development and Product Management. Philip graduated from Taipei Medical College and is a licensed pharmacist.
?@ |
 |
Chi-Hsin Richard King
(Vice President, Chemistry)
Dr. King has over 20 years of medicinal chemistry and chemical development experience in the pharmaceutical industry. Prior to joining TaiGen in July, 2005, Dr. King was at Hoechst Marion Roussel, rising through the ranks to become the Section Head of Chemical Development. He was the inventor of alternative synthetic routes of Fexofenadine HCl, the active ingredient of a world leading nonsedating antihistamine -AllegraTM and its enantiomers. He moved to Union Chemical Laboratories, a division of Taiwan's Industrial Technology Research Institute (ITRI) in1996 where he led a multi-disciplinary pharmaceutical development program as director. Dr. King then joined Albany Molecular Research in 1997 and became Director of Medicinal Chemistry, in charge of both chemical development and discovery chemistry with an emphasis on directing and implementing multiple client projects. Dr. King obtained his Ph.D. degree in organic chemistry from University of Utah.
?@ |
 |
Gene C. Hsu, Ph.D., DABT
(Vice President , Preclinical)
Dr. Hsu joined TaiGen Biotechnology in 2008 as the vice president of preclinical development, responsible for safety pharmacology, toxicology, and drug metabolism/pharmacokinetics. Dr. Hsu has substantial experience in reviewing and evaluating pharmacology and toxicology studies in regulatory submissions as well as designing and conducting exploratory and GLP preclinical studies. His career includes positions of increasing responsibilities at California State and United States Federal governments, and most recently at Merck & Co. Dr. Hsu received his B.S. in Agricultural Chemistry from National Taiwan University (Taiwan), his Ph.D. in Toxicology from Massachusetts Institute of Technology, and completed a postdoctoral fellowship at University of California at Berkley. He is a member of the Society of Toxicology and certified by the American Board of Toxicology as a Diplomate (DABT).
?@ |
|  |
